Verona Pharma price target raised to $90 from $83 at BTIG

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $90 from $83 and keeps a Buy rating on the shares after its Q1 results. The company’s Ohtuvayre sales “continue to breeze along”, as the strong uptake reflects the enormous population of COPD patients that are poorly controlled or could simply feel better, the analyst tells investors in a research note. A final positive sign of patient interest is the better than expected G2N that is now “well below 20%” after management originally guided to 25% based on the experience of Yupelri, the firm added.